Pharmacogenetic and Pharmacogenomic Services

Eurofins – Professional Partner in Pharmacogenetics and Pharmacogenomics

While pharmacogenetics describes genetic variations between individuals and their influence on the efficacy and side effects of drugs, pharmacogenomics examines interactions of drugs with the whole genome: changes of gene expression profiles which are caused by drugs are analysed. The main goal of both fields is the individualised prediction of desirable and undesirable drug effects. Hence, pharmacogenetics and pharmacogenomics are contributing to improve drug treatment and to enable and support the development of drugs, which are safer, more targeted and individualized.

Genetic variability is seen both in the area of pharmacokinetics (absorption, distribution, metabolism and excretion, ADME) and in the area of pharmacodynamics (drug effects). For example genetic variations can influence the activity or have an effect on the expression of drug metabolizing enzymes, drug transporters or G-proteins. Eurofins Medigenomix is offering a comprehensive services portfolio for the entire drug development process, from preclinical research to clinical phase III trials (Eurofins Medigenomix).

One focus: Analysis of G-Proteins, which are playing a central role in cellular signal transduction. Amongst others our pharma services portfolio includes the following services: genotyping, DNA/RNA preparation, SNP/mutation screening, Biomarker analysis, analysis of candidate genes, expression analysis, expression profiling, virus and microbiological diagnostics and assay development/validation. Eurofins Medigenomix is equipped with the latest technical devices for high throughput analysis allowing short turn around times. Eurofins Medigenomix is certified according to ISO 9001 and ISO 17025 and audited by pharmaceutical clients for GxP.

Contact:

Please feel free to discuss your project or study with us:

Phone: +49 8092 8289 200

Email: pharmacogenetics@medigenomix.de